Letrozole and Clomiphene Citrate Effect on Endometrial and Subendometrial Vascularity in Treating Infertility in Women with Polycystic Ovary Syndrome

Impact of letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic ovarian syndrome

“…This was associated with a significant thicker endometrial wall in the letrozole group. This is consistent with previous studies, which reported that most of the patients taking letrozole had a thicker endometrium, resulting in a higher level of VEGF among the pregnant women as compared to the non‐pregnant women in both study groups, Table…”

Effect of clomiphene citrate on endometrial thickness, ovulation, pregnancy and live birth in anovulatory women: systematic review and meta‐analysis

“…In the three studies with low risk of allocation concealment bias, the comparison between CC and letrozole showed lower EMT in the CC group (WMD, −1.68; 95% CI, −3.27 to −0.08; I 2 = 98%). However, including studies with low risk of randomization bias, performance bias and detection bias showed a similar effect estimate but without statistical significance, which could be due to low power of the studies.…”

“…Pooled analysis of 15 studies showed EMT to be lower (WMD, −1.39; 95% CI, −2.27 to −0.51; I 2 = 100%) with a lower pregnancy rate (RR, 0.78; 95% CI, 0.63–0.95; I 2 = 43%) in the CC group than in the letrozole group (Figures and ). Ovulation rates were comparable between the groups (13 trials, RR, 0.97; 95% CI, 0.90–1.04; I 2 = 47%; Figure ). Data of EMT per woman were available in eight studies; pooled analysis showed EMT to be lower in the CC group (WMD, −2.10; 95% CI, −3.22 to −0.98; I 2 = 96%).…”

“…There were 33 RCTs comprising a total of 4349 women with WHO group II anovulation, undergoing 7210 treatment cycles. Of the 33 included studies, participants were women with PCOS (without CC resistance) in 25 studies, women with CC‐resistant PCOS in five studies, women with WHO group II anovulation (with or without PCOS) in two studies and women with WHO group II anovulation (without PCOS) in one study. The characteristics of these 33 included studies are listed in Table .…”

“…Risk of bias for included studies is presented in a summary table ( Figure S1). We included 15 RCTs comparing CC with letrozole (1957 women, 3892 cycles) [23][24][25][27][28][29]33,[38][39][40][41]44,46,51,54 , two RCTs comparing CC with anastrozole (329 women, 329 cycles) 52,53 , two RCTs comparing CC with CC plus metformin (101 women, 140 cycles) 35,42 , three RCTs comparing CC with tamoxifen (571 women, 844 cycles) 26,38,54 , three RCTs comparing CC with CC plus N-acetyl cysteine (NAC; 340 women, 300 cycles) 35,43,49 and two RCTs comparing CC with CC plus isosorbide mononitrate (ISMN) as nitric oxide (NO) donor (120 women, 304 cycles) 30,36 .…”